{
  "extraction_date": "2025-12-23",
  "condition": "SCHIZOPHRENIA",
  "phase": "3",
  "priority": "Expansion",
  "total_studies": 10,
  "studies": [
    {
      "study_id": "CT_NCT04166019",
      "study_type": "RCT",
      "condition": "SCHIZOPHRENIA",
      "study_title": "Effect of a Peer-led Self-management Program for Recent-onset Psychosis",
      "citation": "ClinicalTrials.gov NCTNCT04166019",
      "publication_year": 2025,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Questionnaire about the Process of Recovery (QPR)",
          "Questionnaire about the Process of Recovery (QPR)",
          "Questionnaire about the Process of Recovery (QPR)",
          "Questionnaire about the Process of Recovery (QPR)",
          "Questionnaire about the Process of Recovery (QPR)"
        ],
        "outcome_measures": [
          "Questionnaire about the Process of Recovery (QPR)",
          "Questionnaire about the Process of Recovery (QPR)",
          "Questionnaire about the Process of Recovery (QPR)",
          "Questionnaire about the Process of Recovery (QPR)",
          "Questionnaire about the Process of Recovery (QPR)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04166019",
        "enrollment": 180,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04166019"
      }
    },
    {
      "study_id": "CT_NCT01071135",
      "study_type": "RCT",
      "condition": "SCHIZOPHRENIA",
      "study_title": "Quetiapine XR in Schizophrenic Patients",
      "citation": "ClinicalTrials.gov NCTNCT01071135",
      "publication_year": 2010,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Reduction in PANSS total score"
        ],
        "outcome_measures": [
          "Reduction in PANSS total score"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01071135",
        "enrollment": 5,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01071135"
      }
    },
    {
      "study_id": "CT_NCT02811939",
      "study_type": "RCT",
      "condition": "SCHIZOPHRENIA",
      "study_title": "Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I",
      "citation": "ClinicalTrials.gov NCTNCT02811939",
      "publication_year": 2017,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Active Dronabinol, Placebo Dronabinol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change from Baseline: Positive and Negative Syndrome Scale (PANSS)"
        ],
        "outcome_measures": [
          "Change from Baseline: Positive and Negative Syndrome Scale (PANSS)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02811939",
        "enrollment": 13,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02811939"
      }
    },
    {
      "study_id": "CT_NCT02319746",
      "study_type": "RCT",
      "condition": "SCHIZOPHRENIA",
      "study_title": "COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE",
      "citation": "ClinicalTrials.gov NCTNCT02319746",
      "publication_year": 2019,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Cannabis use reduction in the follow-up",
          "Improvement in the development of psychotic disorder",
          "Changes in the components of the endogenous cannabinoid system",
          "Normalizing the possible alterations in the endogenous cannabinoid system"
        ],
        "outcome_measures": [
          "Cannabis use reduction in the follow-up",
          "Improvement in the development of psychotic disorder",
          "Changes in the components of the endogenous cannabinoid system",
          "Normalizing the possible alterations in the endogenous cannabinoid system"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02319746",
        "enrollment": 88,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02319746"
      }
    },
    {
      "study_id": "CT_NCT01180374",
      "study_type": "RCT",
      "condition": "SCHIZOPHRENIA",
      "study_title": "The Effects of Cannabidiol and \u2206-9-THC in Humans",
      "citation": "ClinicalTrials.gov NCTNCT01180374",
      "publication_year": 2014,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol",
        "delivery_method": "various",
        "dosing_information": "Phase EARLY_PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Behavioral Measures"
        ],
        "outcome_measures": [
          "Behavioral Measures"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01180374",
        "enrollment": 27,
        "phase": "EARLY_PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01180374"
      }
    },
    {
      "study_id": "CT_NCT04945031",
      "study_type": "Clinical Trial",
      "condition": "SCHIZOPHRENIA",
      "study_title": "The Study of Pharmacological Treatment Pattern for Cannabis-induced Psychosis",
      "citation": "ClinicalTrials.gov NCTNCT04945031",
      "publication_year": 2020,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Pharmacological treatment pattern for cannabis-induced psychosis"
        ],
        "outcome_measures": [
          "Pharmacological treatment pattern for cannabis-induced psychosis"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04945031",
        "enrollment": 317,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04945031"
      }
    },
    {
      "study_id": "CT_NCT00783185",
      "study_type": "RCT",
      "condition": "SCHIZOPHRENIA",
      "study_title": "Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment",
      "citation": "ClinicalTrials.gov NCTNCT00783185",
      "publication_year": 2010,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis-Consumption-Reduction-Training",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "PANSS Positive and Negative Symptom Scale"
        ],
        "outcome_measures": [
          "PANSS Positive and Negative Symptom Scale"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00783185",
        "enrollment": 50,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00783185"
      }
    },
    {
      "study_id": "CT_NCT04605393",
      "study_type": "RCT",
      "condition": "SCHIZOPHRENIA",
      "study_title": "Does Cannabidiol Attenuate the Acute Effects of \u22069-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study",
      "citation": "ClinicalTrials.gov NCTNCT04605393",
      "publication_year": 2023,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Hopkins Verbal Learning Test",
          "Positive and Negative Syndrome Scale"
        ],
        "outcome_measures": [
          "Hopkins Verbal Learning Test",
          "Positive and Negative Syndrome Scale"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04605393",
        "enrollment": 36,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04605393"
      }
    },
    {
      "study_id": "CT_NCT01964404",
      "study_type": "RCT",
      "condition": "SCHIZOPHRENIA",
      "study_title": "Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?",
      "citation": "ClinicalTrials.gov NCTNCT01964404",
      "publication_year": 2021,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Dronabinol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Brain Reward Circuit Activation on fMRI Scan",
          "Resting State Connectivity Within the Brain Reward Circuitry"
        ],
        "outcome_measures": [
          "Brain Reward Circuit Activation on fMRI Scan",
          "Resting State Connectivity Within the Brain Reward Circuitry"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01964404",
        "enrollment": 263,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01964404"
      }
    },
    {
      "study_id": "CT_NCT00588731",
      "study_type": "RCT",
      "condition": "SCHIZOPHRENIA",
      "study_title": "Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia",
      "citation": "ClinicalTrials.gov NCTNCT00588731",
      "publication_year": 2013,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Verbal Short Term Memory"
        ],
        "outcome_measures": [
          "Verbal Short Term Memory"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00588731",
        "enrollment": 41,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00588731"
      }
    }
  ],
  "expansion_metadata": {
    "clinicaltrials_gov_added": 10,
    "pubmed_added": 0,
    "total_added": 10,
    "expansion_date": "2025-12-23T23:42:19.538731"
  }
}